COX-2 and neurodegeneration in Parkinson's disease

Annals of the New York Academy of Sciences

Volumn 991, Issue , 2003, Pages 272-277

  Teismann, P ^a   Vila, M ^a   Choi, D K ^a   Tieu, K ^a   Wu, D C ^a   Jackson Lewis, V ^a   Przedborski, Serge ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Inflammation; MPTP; Neurodegeneration; Neurotoxicity; Parkinson's disease; Reactive oxygen species; Superoxide dismutase

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLOOXYGENASE 2; NEUROTOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; CONFERENCE PAPER; DOPAMINERGIC NERVE CELL; ENZYME INDUCTION; ENZYME INHIBITION; MOUSE; NERVE DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA;

ANIMALIA;

EID: 0038389514     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2003.tb07482.x     Document Type: Conference Paper

References (14)

1. WYSS-CORAY, T. & L. MUCKE. 2002. Inflammation in neurodegenerative disease: a double-edged sword. Neuron 35: 419-432.
2. O'BANION, M.K. 1999. Cyclooxygenase-2: molecular biology, pharmacology, and neurobiology. Crit. Rev. Neurobiol. 13: 45-82.
3. VILA, M. et al. 2001. The role of glial cells in Parkinson's disease. Curr. Opin. Neurol. 14: 483-489.
4. KAUFMANN, W.E. et al. 1997. Cyclooxygenases and the central nervous system. Prostaglandins 54: 601-624.
5. HURLEY, S.D. et al. 2002. Cyclooxygenase inhibition as a strategy to ameliorate brain injury. J. Neurotrauma 19: 1-15.
6. PRZEDBORSKI, S. & M. VILA. 2001. MPTP: a review of its mechanisms of neurotoxicity. Clin. Neurosci. Res. 1: 407-418.
7. KNOTT, C. et al. 2000. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16: 724-739.
8. LIBERATORE, G.T. et al. 1999. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5: 1403-1409.
9. WU, D.C. et al. 2002. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22: 1763-1771.
10. HASTINGS, T.G. 1995. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64: 919-924.
11. GRAHAM, D.G. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14: 633-643.
12. AUBIN, N. et al. 1998. Aspirin and salicylate protect against MPTP-induced dopamine depletion in mice. J. Neurochem. 71: 1635-1642.
13. TEISMANN, P. & B. FERGER. 2001. Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39: 167-174.
14. FENG, Z. et al. 2002. Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci. Lett. 329: 354.